Read More: eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient


Kathleen Fanning

Board Director

Ms. Fanning is President and Chief Executive Officer of Mozart Therapeutics, a private Seattle-based biopharmaceutical company focused on the development of novel CD8 T regulatory cell immune modulators in autoimmune and inflammatory diseases. Ms. Fanning has over 35 years of industry experience holding previous leadership roles in both public and private biopharmaceutical companies. Prior to Mozart she served as President and CEO at Nohla Therapeutics; a clinical-stage cell therapy company. During her tenure at Nohla, she provided strategic and operational leadership to quickly transition the company from an academic focus to a fully integrated business.

Prior to Nohla, Ms. Fanning was Chief Operating Officer at VentiRx and was instrumental in the strategic collaboration and company acquisition by Celgene. She has held senior leadership roles at Cell Therapeutics Inc., and CellPro Inc. that included Vice President of Business Development and Vice President of Sales and Marketing where she built and led global sales and marketing organizations. Earlier in her career she spent 13 years at Zeneca Pharmaceuticals (now AstraZeneca) holding positions of ascending responsibility across sales, marketing and early commercial development. Ms. Fanning received her B.A. in Zoology from Miami University in Oxford, Ohio. She also serves as Board Director of Walden Biosciences.